WFG Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

WFG Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$0	Sell	1 -250	-100%	-$3.11K	﹤0.01%	1716
2017 Q1	$4K	Sell	251 -1,800	-88%	-$29.2K	﹤0.01%	1264
2016 Q4	$33K	Sell	2,051 -19,050	-90%	-$345K	0.01%	821
2016 Q3	$383K	Buy	21,101 +15,550	+280%	+$304K	0.1%	218
2016 Q2	$91K	Buy	5,551 +1,400	+34%	+$22.6K	0.02%	527
2016 Q1	$69K	Buy	4,151 +2,101	+102%	+$36.8K	0.02%	579
2015 Q4	$44K	Buy	2,050 +850	+71%	+$16.5K	0.01%	702
2015 Q3	$24K	Buy	+1,200	New	+$37.9K	0.01%	847
2014 Q3	–	Sell	-1,000	Closed	-$16K	–	2194
2014 Q2	$16K	Buy	+1,000	New	+$14.3K	﹤0.01%	1359

Other funds holding HZNP

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

WFG Advisors's HZNP Position: Q2 2017 in Review

WFG Advisors reduced its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 100% in Q2 2017, selling an estimated $3.11K and leaving 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1716.

WFG Advisors first reported a position in HZNP in Q2 2014 and has held it in 9 quarters since. The position peaked at $383K in Q3 2016. 190 funds tracked by Wall St. Rank hold HZNP as of Q2 2017.

WFG Advisors held 1 share of Horizon Therapeutics Public Limited Company Ordinary Shares worth $0 as of Q2 2017.
WFG Advisors sold 250 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2017, an estimated $3.11K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of WFG Advisors's portfolio in Q2 2017, its #1716 holding.
WFG Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2014 and has held it in 9 quarters since.
WFG Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $383K in Q3 2016.
190 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.